AstraZeneca vs Merck & Co

AstraZeneca (AZN), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Merck & Co is worth $354.4B on the stock market and AstraZeneca $283.9B: Merck & Co is valued at 25% more. AstraZeneca trades at 25.9 times earnings and Merck & Co at 145. Over the past year AstraZeneca's share price has moved +2.75% and Merck & Co's +49.8%.

Key facts

AstraZeneca market value
$283.9B
Merck & Co market value
$354.4B
AstraZeneca P/E
25.9
Merck & Co P/E
145
AstraZeneca revenue
$58.7BFY to 2025-12-31
Merck & Co revenue
$65BFY to 2025-12-31
Superinvestors holding both
6

Market values as of .

AstraZeneca vs Merck & Co: every measure side by side
Measure AstraZeneca Merck & Co
SectorHealth CareHealth Care
Country United Kingdom United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$283.9Blower$354.4Bhigher
Revenue$58.7Blower$65Bhigher
Earnings$10.2Blower$18.3Bhigher
Employees96,100higher73,000lower
Total assets$114.1Blower$136.9Bhigher
Valuation
P/E25.9lower145higher
P/S4.8lower5.5higher
P/B—7.9
Dividend yield—2.33%
Profitability
Operating margin23.4%—
Balance sheet
Net assets$48.7Blower$52.6Bhigher
Total liabilities$65.4Blower$84.2Bhigher
Total debt$29.6Blower$49.3Bhigher
Cash on hand$5.7Blower$14.6Bhigher
Price change
Today-0.52%lower-0.48%higher
1 year+2.75%lower+49.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Merck & Co). Who owns AZN · Who owns MRK

Further comparisons

Learn

Questions and answers

Which is bigger, AstraZeneca or Merck & Co?

By market value, Merck & Co is the larger: $354.4B against $283.9B for AstraZeneca. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $58.7B for AstraZeneca.

Which has the higher P/E ratio?

Merck & Co: 145, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Merck & Co: $49.3B, against $29.6B for AstraZeneca. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AstraZeneca and Merck & Co?

In their latest 13F filings, Sarah Ketterer, Brandon Haley, Ken Fisher, Temasek, Dodge & Cox team and Rajiv Jain hold both.

Cite this page

Funkfolio, “AstraZeneca vs Merck & Co”, data as of 17 November 2026. https://funkfolio.com/compare/azn-vs-mrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.